June 2009 Volume 5 Number 6
Visit Nature Reviews Rheumatology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=34&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Rheumatology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=20&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=37&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
*********************************************************************
Nature Reviews Rheumatology Impact Factor: 3.812*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
"Officially endorsed by the Asia Pacific League of Associations for
Rheumatology"
=========================== ADVERTISEMENT ===========================
Poster on Systemic Lupus Erythematosus and Type I Interferon
The study of Systemic Lupus Erythematosus (SLE) patients has revealed a
central role for IFN-a in disease pathogenesis. Nature Immunology with
the generous support of PBL InterferonSource brings a poster providing
an overview of how IFN signaling is intimately involved in SLE pathogenesis.
The poster is available to download FREE to all registered users.
http://links.ealert.nature.com/ctt?kn=85&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Therapy: Once-yearly therapy is enough to stave off glucocorticoid-induced
bone loss
p293 | doi:10.1038/nrrheum.2009.101
http://links.ealert.nature.com/ctt?kn=103&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Therapy: The threat of leflunomide-induced lung disease
p294 | doi:10.1038/nrrheum.2009.39
http://links.ealert.nature.com/ctt?kn=99&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Cannabinoid receptors in SSc
p294 | doi:10.1038/nrrheum.2009.95
http://links.ealert.nature.com/ctt?kn=91&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Spondyloarthropathies: Reading the signs
p295 | doi:10.1038/nrrheum.2009.72
http://links.ealert.nature.com/ctt?kn=2&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Crystal arthritis: The secret of successful long-term gout therapy
p295 | doi:10.1038/nrrheum.2009.73
http://links.ealert.nature.com/ctt?kn=77&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Genetics: New genetic approach confirms importance of IRAK1 in SLE risk
p296 | doi:10.1038/nrrheum.2009.92
http://links.ealert.nature.com/ctt?kn=89&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Stem cells: Progenitor cells found in osteoarthritic tissue
p296 | doi:10.1038/nrrheum.2009.94
http://links.ealert.nature.com/ctt?kn=59&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Pain: Towards individualized therapy for low back pain?
p297 | doi:10.1038/nrrheum.2009.93
http://links.ealert.nature.com/ctt?kn=52&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
IN BRIEF
Connective tissue diseases | Bone Diseases | Rheumatoid arthritis |
Connective tissue diseases
p297 | doi:10.1038/nrrheum.2009.96
http://links.ealert.nature.com/ctt?kn=12&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Genetics: Do kallikrein genes protect against lupus nephritis?
p298 | doi:10.1038/nrrheum.2009.91
http://links.ealert.nature.com/ctt?kn=65&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
IN BRIEF
Rheumatoid arthritis | Therapy | Spondyloarthropathies | Connective tissue
diseases
p298 | doi:10.1038/nrrheum.2009.97
http://links.ealert.nature.com/ctt?kn=26&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Therapy: Herbals and supplements for rheumatic diseases
Donald M. Marcus
p299 | doi:10.1038/nrrheum.2009.89
Many people with chronic rheumatic diseases choose to use complementary
and alternative therapies on the basis of information from unreliable
sources. Does a report from a UK-based arthritis charity meet the need for
rigorous, evidence-based recommendations for the public and for health-care
providers?
http://links.ealert.nature.com/ctt?kn=79&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Connective tissue diseases: New evidence-based guidelines for treating SSc
Janet E. Pope
p300 | doi:10.1038/nrrheum.2009.98
A set of recommendations developed by an international panel of experts
could have an impact on the care of patients with systemic sclerosis.
http://links.ealert.nature.com/ctt?kn=42&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Rheumatoid arthritis: Guidelines for the management of RA: breadth versus
depth
Michael M. Ward
p302 | doi:10.1038/nrrheum.2009.90
The comprehensiveness of clinical guidelines is a major determinant of
their usefulness, but covering a broad range of topics in depth can prove
difficult.
http://links.ealert.nature.com/ctt?kn=40&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Connective tissue diseases: The conundrum of B cell depletion in SLE
Inaki Sanz
p304 | doi:10.1038/nrrheum.2009.100
Two consecutive trials of rituximab, a B-cell-depleting anti-CD20 monoclonal
antibody, have threatened the future of B-cell-targeted therapy for systemic
lupus erythematosus (SLE). While rumors of the demise of this approach
might be greatly exaggerated, the outcomes of these studies should force
academics and the pharmaceutical industry back to the drawing board.
http://links.ealert.nature.com/ctt?kn=102&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Connective tissue diseases: What does the death of Riquent[trade] hold for
the future of SLE?
Joan T. Merrill and Jill P. Buyon
p306 | doi:10.1038/nrrheum.2009.99
In clinical trials testing new treatments for systemic lupus erythematosus
(SLE), the failure of the 15-year drug development program for Riquent[trade]
(abetimus sodium) is the latest in a string of disappointments for a disease
that has seen no new drugs approved in over 50 years.
http://links.ealert.nature.com/ctt?kn=88&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Surgical options for patients with osteoarthritis of the knee
Jorg Lutzner, Philip Kasten, Klaus-Peter Gunther and Stephan Kirschner
p309 | doi:10.1038/nrrheum.2009.88
In cases where symptoms of knee osteoarthritis persist despite conservative
treatment, surgery can be offered to patients. The choice of procedure
from the available options, which include arthroscopy, osteotomy and knee
arthroplasty, is influenced by factors including the location and severity
of joint damage, patient characteristics and risk factors.
Abstract: http://links.ealert.nature.com/ctt?kn=30&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=45&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Tyrosine kinases as targets for the treatment of rheumatoid arthritis
Christina D'Aura Swanson, Ricardo T. Paniagua, Tamsin M. Lindstrom and
William H. Robinson
p317 | doi:10.1038/nrrheum.2009.82
Several cellular responses, in different cell types, are involved in the
pathogenesis of rheumatoid arthritis. Common to many of these responses
is signal transduction through tyrosine kinases. Evidence implicating
certain tyrosine kinases in the pathogenesis of rheumatoid arthritis, and
the potential to inhibit these kinases, is outlined in this Review.
Abstract: http://links.ealert.nature.com/ctt?kn=49&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=74&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Type 17 T helper cells-origins, features and possible roles in
rheumatic disease
Francesco Annunziato, Lorenzo Cosmi, Francesco Liotta, Enrico Maggi and
Sergio Romagnani
Published online: 12 May 2009
p325 | doi:10.1038/nrrheum.2009.80
Type 17 T helper (TH17) cells were first discovered in mice as a distinct
population of T helper cells that produce interleukin-17. Since then, the
origin of human TH17 cells, the factors inducing their differentiation and
the possible role these cells have in the pathogenesis of human rheumatologic
disorders have been matter of intense debate.
Abstract: http://links.ealert.nature.com/ctt?kn=84&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=54&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Endothelial progenitor cell dysfunction in rheumatic disease
Peter E. Westerweel and Marianne C. Verhaar
Published online: 07 May 2009
p332 | doi:10.1038/nrrheum.2009.81
Various rheumatic conditions are characterized by endothelial dysfunction
and a proinflammatory state, both of which can lead to premature
atherosclerosis. Circulating endothelial progenitor cells are involved in
endothelial repair, but the number and function of these cells are affected
in rheumatic diseases, as discussed in this Review.
Abstract: http://links.ealert.nature.com/ctt?kn=60&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=6&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Giant osteoclasts after long-term bisphosphonate therapy: diagnostic
challenges
Nidhi Jain and Robert S. Weinstein
p341 | doi:10.1038/nrrheum.2009.87
This Case Study describes a postmenopausal woman who sustained a vertebral
compression fracture 1 year after discontinuing long-term alendronate
therapy for osteoporosis. A bone biopsy specimen revealed numerous giant,
multinucleated osteoclasts, in contrast to the current opinion that
alendronate therapy reduces the number of osteoclasts. In the context of
this case, the authors highlight diseases that might be associated with
giant osteoclasts, and discuss how to discriminate between them in order
to avoid unnecessary tests and referrals.
Abstract: http://links.ealert.nature.com/ctt?kn=80&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=11&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Systemic lupus erythematosus clinical trials-an interim analysis
Maria Dall'Era and David Wofsy
p348 | doi:10.1038/nrrheum.2009.79
Over the past 5 years, there has been considerable interest in the search
for new treatments for systemic lupus erythematosus; disappointingly,
negative results have now been presented from several large clinical trials.
What can we learn from the experience so far to ensure that future
opportunities for the development of an effective therapy for this disease
are not missed?
Abstract: http://links.ealert.nature.com/ctt?kn=24&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=32&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Reviews Goes Clinical!
In April 2009, Nature Clinical Practice Rheumatology was completely
redesigned and became Nature ReviewsRheumatology, bringing all the qualities
of the top-ranked* life science review series to the clinical sciences.
For more information visit:
http://links.ealert.nature.com/ctt?kn=97&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
*2007 Journal Citation Report (Thomson Reuters, 2008)
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=14&m=33353619&r=MTc2NDQ4MTc5OAS2&b=2&j=NTA4MjAxNzES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
